Slides
Page 1
Supplementary Information of Consolidated Financial Results for the Nine Months ended December 31, 2025 Feb 13, 2026 Linical Co., Ltd. *Please note that this translation is to be used solely as reference. In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.
Page 2
Consolidated Financial Results 2 Units: Millions of yen, % Results for the Nine Months Ended December 31, 2024 Results for the Nine Months Ended December 31, 2025 Amount Net Sales Amount Net Sales Year-on- Year Net Sales 7,955 100.0 6,837 100.0% △14.0 Cost of Sales 6,097 76.6 5,726 83.8% △6.1 SG&A Expenses 2,189 27.5 2,388 34.9% 9.1 Operating Profit △332 △4.2 △1,277 △18.7% － Ordinary Profit △261 △3.3 △1,233 △18.0% － Net Profit △316 △4.0 △1,551 △22.7% － Net Sales Net sales increased year-on-year in Japan, Europe, Taiwan and China due to change orders for existing projects and acquisition of new projects, but decreased on a consolidated basis due to decreased sales in the US and South Korea. Operating Profit Positive operating income in Taiwan and China, and operating loss decreased in Japan, but operating loss increased on a consolidated basis due to significant impact of operating loss in the US and Europe.
Page 3
Financial Results by Region 3 Unit: Millions of yen Results for the Nine Months Ended December 31, 2024 Results for the Nine Months Ended December 31, 2025 Net Sales ** Operating Profit Ordinary Profit Net Sales ** Rate of Change % Operating Profit Rate of Change % Ordinary Profit Rate of Change % Japan 2,794 △374 △346 2,958 5.9 △305 － △179 － United States 3,603 543 575 2,407 △33.2 △348 － △327 － Europe 2,334 △63 △101 2,424 3.8 △316 － △394 － Korea 544 △91 △37 489 △10.1 △90 － △110 － Taiwan 58 △37 △36 151 160.5 17 － 15 － China 155 1 △1 194 24.6 44 3,728.4 40 － Consolidation Adjustments* △1,535 △309 △313 △1,788 － △278 － △277 － Total 7,955 △332 △261 6,837 △14.0 △1,277 － △1,233 － * Amortization of goodwill is included in consolidation adjustments. ** Net sales have calculated before deducting internal transactions.
Page 4
Financial Results by Region Japan: Sales increased and operating loss narrowed due to multiple new projects awarded from pharmaceutical companies in Japan and overseas. Aim to improve performance through initiatives to raise personnel utilization and rigorous expense control. US: Sales decreased due to inability to compensate for decreased sales resulting from completion of large-scale projects, resulting in operating loss. Despite unofficial acceptance of orders for several large-scale global clinical trials, these did not contribute to sales because the government shutdown delayed the start of trials. Europe: Revenues increased due to change orders for existing projects that extended the duration of existing projects and added man-hours. Operating loss expanded due to an increase in outsourcing costs and other expenses. Asia: Korea: Substantial decrease in revenue due to suspension of multiple projects for customer reasons, but slight decrease in operating loss China: Increase in revenue and profit due to cost reduction Taiwan: Increase in revenue and operating profit due to acquisition of new projects, etc. 4
Page 5
* Hard backlog: The balance of the amount for orders for contract business already concluded. This is an indicator that shows the amount of sales to be generated over the next one to five years and serves as the basis for the group's future results forecasts. 4,350 4,191 4,765 4,242 4,378 2,756 2,212 2,578 2,242 2,892 3,192 2,705 2,422 2,188 3,387 1,437 1,790 2,031 1,948 2,043 0 5,000 10,000 15,000 2025/3 2025/6 2025/9 2025/12 2026/2/13 Asia EU US Japan 11,737 10,898 10,622 12,70211,797 5 • The hard backlog as of February 13, 2026 was 12.7 billion yen, up 8.2% from the end of March 2025 Hard Backlog by Region (Millions of yen)
Page 6
Hard Backlog in each region Japan and Asia: • Increased hard backlog in Japan, Taiwan, and South Korea compared to the end of March 2025 due to the acquisition of multiple new orders. • Increasing trend in wins for Global clinical trial projects from US/European biotechs that include Japan and Asia and development projects from Japanese/Asian pharma and biotech companies targeting entry via Australia or direct access to the North American market. US: • Hard backlog increased compared to the end of March 2025 due to the completion of contracts for some of the large-scale international clinical trials in the United States, Europe, and Australia, as well as the completion of contracts for new projects mainly to be conducted in the United States. Continue to strengthen sales and proposals to win orders as there were many inquiries for new projects, including global projects. Europe: • Hard backlog increased compared to the end of March 2025 due to the completion of contracts for new projects mainly to be conducted in Europe, as well as the change orders for existing projects and the abovementioned US’s completion of contracts for the European portion of the large-scale international clinical trials. • Expanding project wins from US companies, including Europe-related projects, through enhanced collaboration with our US operations, while strengthening our European sales presence. 6
Page 7
7 Unit: Millions of yen FY ended March 2025 FY ending March 2026 forecasts Amount Sales Ratio Amount Sales Ratio Rate of Change Net Sales 10,437 100.0 9,350 100.0% △10.4% Operating Profit △583 △5.6 △1,350 △14.4% － Ordinary Profit △498 △4.8 △1,400 △15.0% － Net Profit △539 △5.2 △1,700 △18.2% － Amount (yen) Payout ratio (%) Amount (yen) Payout ratio (%) Dividend per share 16.00 － 16.00 － Full-Year Forecast (2,000) 0 2,000 4,000 6,000 8,000 10,000 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 Net Sales Operating Profit
Page 8
Cautionary Notes Those plans, forecasts, strategies, etc., stated in this document that are not historical facts are forecasts concerning future results. These are forecasts that have been determined by the company based on information currently available so please do not place undue reliance on them. Please understand that the company will bear no responsibility whatsoever for any damage, etc., resulting from errors in the information stated in this document. In addition, this document is not aimed at soliciting investment. Users are asked to make investment decisions at their own judgment. 8